Is budenofalk (budesonide) safe to use during pregnancy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Budesonide (Budenofalk) is Safe During Pregnancy

Budesonide is the preferred inhaled corticosteroid for use during pregnancy, with the most reassuring safety data and no evidence of increased risk for major malformations, preterm delivery, or adverse perinatal outcomes. 1

Evidence Supporting Safety

The most recent and authoritative guideline evidence comes from the 2020 ERS/TSANZ Task Force, which classifies budesonide as Category A (TGA) and Category B (FDA) and rates it as "Compatible" for use throughout pregnancy 1. This represents the highest safety classification among inhaled corticosteroids.

Key Safety Findings:

  • No increased risk of major malformations at usual therapeutic doses
  • No increased risk of intrauterine growth restriction (IUGR), preterm delivery, or low birth weight
  • More pregnancy safety data available for budesonide than any other inhaled corticosteroid 2, 1

Multiple large registry studies from Sweden, Australia, Canada, Hungary, Japan, and the US consistently demonstrate no increased risk for congenital malformations, cardiovascular defects, or adverse pregnancy outcomes compared to the general population 3.

Clinical Recommendations

For Asthma During Pregnancy:

The 2005 NAEPP guidelines (updated 2004) specifically state: "Budesonide is the preferred inhaled corticosteroid because more data are available on using budesonide in pregnant women than are available on other inhaled corticosteroids, and the data are reassuring." 2

Important Caveats:

  • If a woman is already well-controlled on another inhaled corticosteroid before pregnancy, she can continue that medication rather than switching, as changing formulations may jeopardize asthma control 2, 1
  • Uncontrolled asthma poses greater risk to both mother and fetus than the medication itself
  • Use the lowest effective dose necessary to maintain asthma control 1

Dosing Considerations:

One study showed that beclomethasone doses >1000 µg/day were associated with a small risk of congenital malformation 1. This reinforces the principle of using the minimum effective dose, though budesonide itself has not shown this dose-dependent risk.

Formulation-Specific Data

The evidence primarily supports:

  • Inhaled budesonide for asthma (extensive data)
  • Topical/intranasal budesonide for rhinitis (reassuring safety profile) 4, 5

For gastrointestinal formulations (Budenofalk specifically for Crohn's disease), while systemic absorption is minimal due to extensive first-pass hepatic metabolism 6, the pregnancy data are less extensive than for inhaled formulations. However, the same pharmacological principles apply—minimal systemic exposure translates to minimal fetal exposure.

Breastfeeding

Budesonide is compatible with breastfeeding 1. The minimal systemic absorption and low levels in breast milk do not pose risk to the nursing infant.

Bottom Line Algorithm

  1. Is asthma/inflammatory condition controlled? If yes, continue current budesonide regimen
  2. Starting new therapy? Choose budesonide as first-line inhaled corticosteroid
  3. Already on different ICS and well-controlled? May continue rather than switch
  4. Use lowest effective dose to maintain control
  5. Monitor asthma control closely—uncontrolled asthma is more dangerous than the medication

The 25+ years of clinical experience with budesonide in pregnancy, combined with multiple large registry studies and guideline endorsements, make it the gold standard for corticosteroid therapy when needed during pregnancy 2, 1, 3.

References

Research

Safety of intranasal corticosteroid sprays during pregnancy: an updated review.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2018

Research

Allergy Medications During Pregnancy.

The American journal of the medical sciences, 2016

Research

Drugs in focus: Budesonide and its role in paediatric gastrointestinal disorders.

Journal of pediatric gastroenterology and nutrition, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.